The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study
Letizia Porcelli(Istituto Tumori Bari), Amalia Azzariti(Istituto Tumori Bari)
Cited by 36
Related Papers
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
|Molecular Cancer|2022|147
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination
|Hepatology|2016|102
Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
|Frontiers in Cell and Developmental Biology|2023|16